Genopole, France’s leading biopark for life sciences research, and Amgen, a pioneer in medical biotech, have joined forces to co-organize the International Colloquium on Innovation. The objective of the event is to better understand 1- the organization of innovation systems throughout the world 2- the specificities of major innovation sectors and channels including 3- those of biomedical innovation 4- the role of regions in innovation with the goal of identifying best practices through (...)
In collaboration with its partners, Genopole, France’s leading biopark, is organizing the third edition of its competition for biotech startups focused on the environment, agronomy and/or industry (excluding the medical sector). This year, the competition is placed under the auspices of three French Ministries : Research, Industrial Renewal and Ecology and is sponsored by Chimex and Bongrain. The competition is intended for project holders or young startups looking to develop an innovation (...)
Genopole®, France’s leading biotech- and biotherapy-dedicated science and business park, is committed to debating the societal and ethical aspects of the life sciences.
On December 14, 2010, Genopole® will hold the third edition of its Biomanufacturing Symposium, entitled “30 years of therapeutic product biomanufacturing : outcomes and outlook”. Following the success of the two previous editions of the Biomanufacturing Symposium, Genopole® will broaden its outlook and ask the following question : which expression systems, compounds, technologies, drug targets and business models will be critically important in biomanufacturing in the future ? The symposium (...)
You can find webcasts of some of the lectures and of the slides following this link. Note that you need to install the silverlight plugin. With the advent of high-throughput DNA sequencing and synthesis, it became possible to produce a list of molecular parts composing a living organism. Deconstruction of such parts can help us in the simplification of the existing organisms to be used later for grafting new functionalities. This Top-Down approach to Synthetic Biology has produced (...)
Ever since Paul Berg’s call in the early 1970s for contemporary debates on stem cells or synthetic biology and more recent controversies concerning GMOs, the life sciences and technologies have been at the heart of the relationship between science and society. What types of regulations and controls should be placed on scientific research ? Is regulation of the applications of research enough, or should research itself be regulated ? Where does research freedom stop and at what point should (...)